CN112957326A - Sodium pyruvate nasal spray and preparation method thereof - Google Patents
Sodium pyruvate nasal spray and preparation method thereof Download PDFInfo
- Publication number
- CN112957326A CN112957326A CN202110264742.5A CN202110264742A CN112957326A CN 112957326 A CN112957326 A CN 112957326A CN 202110264742 A CN202110264742 A CN 202110264742A CN 112957326 A CN112957326 A CN 112957326A
- Authority
- CN
- China
- Prior art keywords
- sodium pyruvate
- nasal spray
- surfactant
- nasal
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the field of pharmaceutical preparations, in particular to a sodium pyruvate nasal spray and a preparation method thereof. The composition is characterized by comprising the following components: sodium pyruvate, a drug carrier, a surfactant, a stabilizer, a preservative and physiological saline. The hydroxypropyl cellulose is dissolved in the nasal spray, so that the viscosity of the nasal preparation can be effectively increased, the sprayed aerial fog is contacted with nasal mucosa in tiny liquid drops, the medicine is uniformly dispersed, the distribution area is wide, the detention time is long, and the absorption is complete. Meanwhile, the Gemini quaternary ammonium salt cationic surfactant with good wettability, bactericidal property and high emulsifying capacity is added into the prescription, so that the effects of dissolving nasal mucosa mucus and effectively removing dirt and other substances can be realized.
Description
Technical Field
The invention relates to the field of medicinal preparations, in particular to a sodium pyruvate nasal spray and a preparation method thereof.
Background
In recent years, the administration through the nasal mucosa is considered as an administration mode that the medicine can be absorbed quickly and efficiently, a plurality of fine villi are arranged on nasal mucosa cells, so that the effective area of medicine absorption is greatly increased, abundant blood vessels and lymphatic vessels are arranged below the mucosa cells, the medicine can directly enter the systemic circulation after being absorbed through the mucosa, in addition, the metabolism of enzymes in the nasal cavity is far smaller than that of the gastrointestinal tract, and therefore, the nasal administration system is increasingly paid attention by people. The nasal cavity is used as the administration part, and compared with other parts, the medicine absorption of the nasal cavity has the following characteristics: the medicine is convenient to be administrated by dripping or spraying, and the patient can finish the medicine administration by himself. Secondly, the nasal mucosa has a plurality of fine villi which can obviously increase the surface area of the drug absorption, and simultaneously, the epithelial cells have a plurality of abundant capillary vessels, so the drug can be absorbed rapidly. The medicament directly enters systemic circulation after being absorbed, has no liver first-pass effect, has low activity of proteolytic enzyme in nasal mucosa, and is an effective administration route for peptide and protein medicaments which are easy to metabolize in gastrointestinal fluids and gastrointestinal wall membranes or have large first-pass effect. The nasal mucosa has higher permeability than the human mucosa of other parts, such as gastrointestinal tract, oral cavity, vagina and the like, and the medicine can be well absorbed.
The nasal spray is a clear solution, suspension or emulsion prepared from raw material medicines and proper auxiliary materials, and is a nasal liquid preparation for atomization by a sprayer, and because a quantitative pump and a spray head are used, the nasal spray can accurately release 25-200 mu L of dosage, and the size and the form of medicine particles and the viscosity of the preparation are determined by the selection of the pump and the spray head. After the medicine is sprayed, the medicine is contacted with nasal mucosa in tiny liquid drops, and the medicine is uniformly dispersed, wide in distribution area, long in detention time and complete in absorption. Currently marketed nasal sprays, naloxone hydrochloride nasal spray, levocabastine hydrochloride nasal spray, azelastine hydrochloride nasal spray, salmon calcitonin nasal spray, beclomethasone dipropionate nasal spray, and the like.
The sodium pyruvate is a normal component in human bodies and animal bodies, is a basic metabolism of organisms, has a remarkable protective effect on the functions of multiple cells and multiple organs, is particularly used for repairing ischemia/reperfusion injury of hearts, livers, brains and kidneys, and has no toxic or side effect. Sodium pyruvate is a drug developed by EmphyCorp Inc for the treatment of asthma, cancer, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease and viral infections.
Sodium pyruvate, its formula C3H3NaO3Molecular weight 110.044, having the formula:
at present, the field aims to provide a nasal spray containing sodium pyruvate, which is atomized by a portable atomizer, contacts nasal mucosa by tiny liquid drops, and has the advantages of uniform dispersion of the medicine, wide distribution area, long retention time and complete absorption. Many attempts have been made to develop nasal delivery systems, such as nasal sprays.
CN102657611B discloses a nasal spray containing sodium pyruvate and a preparation method thereof, which is characterized by comprising the following components: sodium pyruvate, pyruvic acid, an isotonic regulator, a preservative and water. The nasal spray therapy liquid is prepared and enters the nasal cavity through a portable spraying device, and is particularly suitable for cleaning and removing harmful pollutants in nasal passages, nasal sinuses and mucociliary. However, the nasal spray has a limited effect of cleaning nasal mucus because water is used for cleaning.
CN103735581B discloses a nasal cavity cleaning and nursing solution and a preparation method thereof, wherein the cleaning and nursing solution is prepared from 5000 parts by weight of traditional Chinese medicine distillate, 0.1-2 parts by weight of preservative, 1-100 parts by weight of lubricating humectant, 20-100 parts by weight of Tween 80, 30-80 parts by weight of sodium chloride, 20-60 parts by weight of pH value regulator and 4658-4928.9 parts by weight of purified water, the osmotic pressure of the nursing solution is 280-310 mosm/Kg, and the pH value is 5.5-7.0. The preferred tween 80 in the invention is used as a solubilizer and a stabilizer, which is effective for the stability of the solution. However, the residence time of the drug on the nasal mucosa is short, which has an effect on the nasal mucosal absorption of the drug.
The inventors thought that by adding a prescribed amount of surfactant to the prescription, it could achieve the effect of dissolving nasal mucosa mucus, effectively removing dirt and other substances. Meanwhile, a medicine carrier capable of effectively increasing the viscosity of the sodium pyruvate nasal spray is added, and tiny liquid drops are contacted with nasal mucosa, so that the medicine is uniformly dispersed, wide in distribution area, long in detention time and complete in absorption.
Disclosure of Invention
The invention aims to solve the technical problems and find a proper surfactant to realize the effects of dissolving nasal mucosa mucus and effectively removing dirt and other substances. The medicine carrier can effectively increase the viscosity of the sodium pyruvate nasal spray, and the tiny liquid drops are contacted with nasal mucosa, so that the medicine is uniformly dispersed, has wide distribution area, long detention time and complete absorption.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
a sodium pyruvate nasal spray and a preparation method thereof comprise the following steps:
a sodium pyruvate nasal spray comprises sodium pyruvate, a drug carrier, a buffer system, a surfactant, a stabilizer, a preservative and water.
The inventor finds in research that the selection of the pharmaceutical carrier is crucial for the preparation of sodium pyruvate nasal spray. The sodium pyruvate nasal spray comprises the following components:
(a) the sodium pyruvate nasal spray comprises sodium pyruvate active ingredients which account for 0.1-0.4%, preferably 0.15-0.3% of the nasal spray dosage;
preferably, the unit dosage form of the sodium pyruvate nasal spray comprises 0.22% of the sodium pyruvate active ingredient in the nasal spray dosage.
(b) The sodium pyruvate nasal spray comprises one or more pharmaceutically acceptable drug carriers:
it has been found from extensive literature studies that increasing the viscosity of nasal formulations can prolong the therapeutic effect. Such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, copovidone, and other drug carriers, which are effective in improving the absorption of low molecular weight drugs.
Preferably, in the sodium pyruvate nasal spray, the acceptable pharmaceutical carrier is hydroxypropyl cellulose.
Furthermore, in the sodium pyruvate nasal spray, the unit dose of nasal spray contains 0.02-0.05% of hydroxypropyl cellulose.
(c) The sodium pyruvate nasal spray comprises the following pharmaceutically acceptable stabilizers:
preferably, in the sodium pyruvate nasal spray, a suitable pharmaceutically acceptable stabilizer comprises one or more of ethylene glycol, a small amount of ethanol, medium chain glycerides, mannitol, lactose, or albumin, pyruvic acid, and the like.
Further preferably, in the sodium pyruvate nasal spray, the stabilizer is preferably one or more of medium chain glyceride, ethylene glycol and pyruvic acid.
Still further preferably, said stabilizer is preferably pyruvic acid.
Still further preferably, the unit dose of nasal spray comprises pyruvic acid in the range of 0.01-0.05%.
(d) The sodium pyruvate nasal spray comprises the following pharmaceutically acceptable preservatives:
the term "preservative" as used in the present invention means that a preservative is added to the liquid nasal preparation to prevent bacterial growth. Suitable preservatives include one or more of benzalkonium chloride, phenylethyl alcohol, polyhexamethylene biguanide, parabens, benzoic acid, sorbic acid and the like.
Further preferably, in the sodium pyruvate nasal spray, the medicinal preservative is preferably one or more of benzalkonium chloride, polyhexamethylene biguanide and sorbic acid.
Still further preferably, in the sodium pyruvate nasal spray, the medicinal preservative is preferably benzalkonium chloride.
Even more preferably, the unit dose nasal spray comprises 0.01% benzalkonium chloride.
(e) The sodium pyruvate nasal spray comprises the following components in parts by weight:
the term "physiological saline" used in the present invention, also called sterile physiological saline, refers to a sodium chloride solution having an osmotic pressure substantially equal to that of plasma of an animal or human body, which is commonly used in physiological experiments or clinical practice.
(f) The sodium pyruvate nasal spray comprises the following pharmaceutically acceptable surfactants:
the term "surfactant" as used herein means a surfactant that is highly soluble in nasal mucus, effectively removes dirt and other substances, and remains stable for a long period of time. Suitable surfactants include one or more of benzalkonium chloride, disodium cocoimidazoline diacetate, sodium diethylhexyl sulfosuccinate, ammonium cocoyl amide, ammonium cocoisothionate, and Gemini-type surfactants, among others.
Further preferably, in the sodium pyruvate nasal spray, the pharmaceutically acceptable surfactant is preferably one or more of benzalkonium chloride, disodium cocoimidazoline diacetate and a Gemini type surfactant.
Still further preferably, in the sodium pyruvate nasal spray, the pharmaceutically acceptable surfactant is preferably a Gemini type surfactant.
Still more preferably, the Gemini surfactant has a molecular structure different from that of the classical surfactant, and the Gemini molecule at least comprises two hydrophilic groups (ionic or polar groups) and two hydrophobic chains, and the hydrophilic groups or the hydrophilic groups are connected together by a linking group (sPacer) through a chemical bond (covalent bond or ionic bond). The hydrophilic group constituting the Gmiin type surfactant may be a cation (e.g., quaternary salt), an anion (e.g., phosphate, sulfate, sulfonate, and carboxylate, etc.), a zwitterion, a nonionic and a cationic ion (catanioni), an ion pair (ion-hair), or the like. The hydrophobic moiety is typically a CH chain (about 8-20C atoms in length, sometimes containing oxygen or phenyl groups), and more recently a CF chain. The connecting group has various varieties and can be short-chain (2 atoms) or long-chain (more than 20 atoms); a rigid chain (e.g., stilbene) or a flexible chain (e.g., a plurality of methylene groups); polar chains (e.g., polyethers) or nonpolar chains (e.g., aliphatic and aromatic), and the like.
Furthermore, the Gemini type surfactant is a Gemini quaternary ammonium salt cationic surfactant which has a rigid structure isophthaloyl dichloride group as a connecting arm, and has good wettability, bactericidal property and high emulsifying capacity.
Still more preferably, the unit dose nasal spray contains 0.05-0.2% of a Gemini surfactant.
The invention also aims to provide a using method of the nasal spray, which comprises the following steps:
(1) and taking down the bottle cap.
(2) The nasal spray bottle is held by hand, the bottle cap is pressed with strength, then the operation is relaxed and repeated (1-2 times) until uniform and fine aerial fog is released, and the nasal spray bottle can be used.
(3) The nozzle of the spray bottle is inserted into one nostril at one side to ensure that the mouth of the bottle is in line with the nasal cavity, and the cap is pressed once and then loosened.
(4) After one dose of spray pressure, the patient inhales deeply with the nose for several times to prevent the medicine from flowing out of the nostrils, and the patient does not need to immediately exhale with the nostrils.
(5) If the doctor lets you administer two sprays at a time, the procedure is repeated once in the other nostril.
(6) The bottle cap is covered after each time of use.
(7) Once used, the spray bottle should be stored at room temperature and used up in four weeks.
(8) If the sprayer becomes clogged, it can be deactivated by forcefully pressing on the actuating means, without the use of a sharp object, which could damage the sprayer.
Detailed Description
The advantages of the present invention are further described below by way of examples, it being properly understood that: the examples of the present invention are given solely for the purpose of illustration and not as limitations of the present invention, and therefore, simple modifications of the present invention in the context of the methods of the present invention are intended to fall within the scope of the claims.
Example 1
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 1 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate and pyruvic acid in the prescription amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the prescription amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Example 2
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 2 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate, pyruvic acid and hydroxypropyl cellulose in the formula amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the formula amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Example 3
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 3 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate, pyruvic acid and hydroxypropyl cellulose in the formula amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the formula amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Example 4
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 4 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate, pyruvic acid and hydroxypropyl cellulose in the formula amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the formula amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Example 5
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 5 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate, pyruvic acid and hydroxypropyl cellulose in the formula amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the formula amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Example 6
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 6 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate, pyruvic acid and hydroxypropyl cellulose in the formula amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the formula amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Example 7
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 7 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate, pyruvic acid and hydroxypropyl cellulose in the formula amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the formula amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Example 8
The sodium pyruvate nasal spray and the preparation method thereof in the embodiment comprise the following steps:
1) prescription
TABLE 8 sodium pyruvate nasal spray formulation
2) Preparation process
Slowly adding sodium pyruvate, pyruvic acid and hydroxypropyl cellulose in the formula amount into 9500g of normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolution, adding benzalkonium chloride and a Gemini surfactant in the formula amount, uniformly stirring, adjusting the pH to 6.0 by using 0.1mol/L sodium hydroxide solution, then fixing the volume to 10000g by using the normal saline, filtering, and filling.
Verification examples
Test example 1
Stability test of sodium pyruvate nasal spray
And (3) accelerated test: the nasal spray of the embodiment 1-8 is put in a constant temperature and humidity box with 40 +/-2 ℃/75 +/-5% RH, and then sampled at 0, 1, 2, 3 and 6 months respectively, and then the appearance, the pH value, the clarity and the color of the solution and the related substances and contents are observed. The result shows that the appearance, the pH value, the related substances and the content of the preparation are basically consistent with the analysis result of the same batch of samples before the test after 6 months under the condition of 40 +/-2 ℃/75 +/-5% RH, which indicates that the preparation is stable.
And (4) reserving a sample at room temperature: after the samples of the examples 1 to 8 are stored at room temperature for a period of time, the samples are compared with the analytical data of the same batch of samples before the experiment, and the results show that the preparation is kept for 18 months at room temperature, and the appearance, the pH value, the related substances and the content measurement results are basically consistent. The experimental result shows that the preparation has good stability.
Test example 2
According to the determination and detection of the sterile preparation in the Chinese pharmacopoeia 2015 edition, the result shows that the positive control tube has bacterial growth and good growth, and the negative control tube has no bacterial growth. The results indicate that the present formulation is sterile.
The beneficial effects of the present invention are further illustrated by the following tests:
the test method comprises the following steps: in each example, 30 rhinitis and nasal obstruction patients are selected for experiments, wherein the sodium pyruvate nasal spray obtained in example 1-8 is taken for half of men and women, 1-2 sprays are taken each time, and the nasal spray is taken in the morning, at noon and at night.
The using method comprises the following steps: (1) taking down the bottle cap; (2) holding the nasal spray bottle, pressing the bottle cap with force, then relaxing, and repeating the operation (1-2 times) until uniform and fine aerial fog is released, so that the nasal spray bottle can be used; (3) inserting a nozzle of the spray bottle into one nostril at one side to ensure that the bottle mouth and the nasal cavity are in a straight line, and pressing and loosening the bottle cap once; (4) after one dose of spraying pressure, deeply inhaling for several times by using a nose so as to prevent the medicine from flowing out of nostrils and ensure that the nostrils do not need to be used for exhaling immediately; (5) if the doctor lets you administer two sprays at a time, the procedure is repeated once in the other nostril. The examination is carried out 7 days after the test, the number of the patients with obvious effect, improvement and ineffectiveness is counted, and the total effective rate is calculated. The therapeutic effect judgment standard is as follows: the method has the following advantages: no obvious nasal obstruction symptom exists, and the nose feels comfortable; improvement: the nasal obstruction still has the symptoms, but is relieved compared with the symptoms before the medicine is taken; ③ invalid: the symptoms are not obviously improved. The results are shown in Table 9.
| Group of | Patient (example) | Show effect | Improvement of life | Invalidation | Total effective rate/%) |
| Example 1 | 30 | 20 | 9 | 1 | 96.7 |
| Example 2 | 30 | 27 | 3 | 0 | 100 |
| Example 3 | 30 | 25 | 5 | 0 | 100 |
| Example 4 | 30 | 23 | 6 | 1 | 96.7 |
| Example 5 | 30 | 21 | 8 | 1 | 96.7 |
| Example 6 | 30 | 17 | 12 | 1 | 96.7 |
| Example 7 | 30 | 19 | 10 | 1 | 96.7 |
| Example 8 | 30 | 20 | 8 | 2 | 93.3 |
The test results of the embodiments 1 to 8 show that the sodium pyruvate nasal spray has very remarkable treatment effect on rhinitis nasal plugs, can effectively remove pollutants, foreign bacteria, viruses, allergens and various dusts in nasal cavities from being retained on the upper respiratory tract of people, and is high in safety and convenient to carry.
Claims (7)
1. The sodium pyruvate nasal spray is characterized by comprising the following raw and auxiliary materials: sodium pyruvate, a drug carrier, a surfactant, a stabilizer, a preservative and physiological saline.
2. The sodium pyruvate nasal spray of claim 1, wherein the unit dose of the nasal spray comprises 0.1 to 0.4% sodium pyruvate.
3. The sodium pyruvate nasal spray of claim 1, wherein the sodium pyruvate nasal spray comprises one or more pharmaceutically acceptable pharmaceutical carriers, the stabilizer is one or more of mannitol, lactose, albumin, and pyruvic acid, the preservative is one or more of benzalkonium chloride, phenethyl alcohol, polyhexamethylene biguanide, parabens, benzoic acid, and sorbic acid, and the surfactant is one or more of benzalkonium chloride, disodium cocoimidazoline diacetate, sodium diethylhexyl sulfosuccinate, ammonium cocoyl carbamate, ammonium cocoisothionate, and a Gemini surfactant.
4. The sodium pyruvate nasal spray according to claim 3, wherein a drug carrier is hydroxypropyl cellulose, a stabilizer is pyruvic acid, a preservative is benzalkonium chloride, and a surfactant is a Gemini type surfactant.
5. The sodium pyruvate nasal spray of claim 4, wherein the unit dose of nasal spray comprises 0.02-0.05% hydroxypropyl cellulose, 0.01-0.05% pyruvic acid, 0.01% benzalkonium chloride, and 0.05-0.2% Gemini surfactant.
6. The sodium pyruvate nasal spray according to claim 1, which is characterized by comprising the following steps: slowly adding sodium pyruvate, a drug carrier and a stabilizer into normal saline respectively, heating to 40-50 ℃, fully stirring, cooling to a room temperature state after dissolving, adding a preservative and a Gemini surfactant, uniformly stirring, adjusting the pH to 6.0 by using a sodium hydroxide solution, fixing the volume by using the normal saline, filtering and filling.
7. The sodium pyruvate nasal spray according to claim 6, which is characterized by comprising the following steps: 22g of sodium pyruvate, 5g of hydroxypropyl cellulose and 5g of pyruvic acid are slowly added into 9500g of normal saline respectively, the mixture is heated to 40-50 ℃ and fully stirred, after dissolution, the temperature is reduced to the room temperature state, then 1g of benzalkonium chloride and 10g of Gemini surfactant are added and uniformly stirred, then 0.1mol/L sodium hydroxide solution is used for adjusting the pH value to 6.0, then the normal saline is used for fixing the volume to 10000g, and the mixture is filtered and filled.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110264742.5A CN112957326A (en) | 2021-03-11 | 2021-03-11 | Sodium pyruvate nasal spray and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110264742.5A CN112957326A (en) | 2021-03-11 | 2021-03-11 | Sodium pyruvate nasal spray and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112957326A true CN112957326A (en) | 2021-06-15 |
Family
ID=76277235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110264742.5A Pending CN112957326A (en) | 2021-03-11 | 2021-03-11 | Sodium pyruvate nasal spray and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112957326A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481429A (en) * | 2019-01-22 | 2019-03-19 | 广州蓓思语生物科技有限公司 | A kind of nasal nursing spray |
| CN115671051A (en) * | 2022-10-24 | 2023-02-03 | 江苏长泰药业有限公司 | Sodium pyruvate nasal spray and application thereof |
| CN115721726A (en) * | 2022-07-27 | 2023-03-03 | 江苏长泰药业有限公司 | Nasal cavity product for preventing or relieving cold symptoms and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481429A (en) * | 2019-01-22 | 2019-03-19 | 广州蓓思语生物科技有限公司 | A kind of nasal nursing spray |
-
2021
- 2021-03-11 CN CN202110264742.5A patent/CN112957326A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481429A (en) * | 2019-01-22 | 2019-03-19 | 广州蓓思语生物科技有限公司 | A kind of nasal nursing spray |
Non-Patent Citations (1)
| Title |
|---|
| 林宁: "《生物药剂学与药物动力学》", 30 June 2017, 中国中医药出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481429A (en) * | 2019-01-22 | 2019-03-19 | 广州蓓思语生物科技有限公司 | A kind of nasal nursing spray |
| CN115721726A (en) * | 2022-07-27 | 2023-03-03 | 江苏长泰药业有限公司 | Nasal cavity product for preventing or relieving cold symptoms and preparation method thereof |
| CN115721726B (en) * | 2022-07-27 | 2023-10-17 | 江苏长泰药业股份有限公司 | Nasal product for preventing or relieving cold symptoms and preparation method thereof |
| CN115671051A (en) * | 2022-10-24 | 2023-02-03 | 江苏长泰药业有限公司 | Sodium pyruvate nasal spray and application thereof |
| CN115671051B (en) * | 2022-10-24 | 2024-03-05 | 江苏长泰药业股份有限公司 | Sodium pyruvate nasal spray and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112957326A (en) | Sodium pyruvate nasal spray and preparation method thereof | |
| TWI228998B (en) | Method and device for delivering an active agent to the lungs | |
| US9724382B2 (en) | Pharmaceutical compositions comprising cyclosporin | |
| Singh et al. | Nasal cavity, a promising transmucosal platform for drug delivery and research approaches from nasal to brain targetting | |
| JP2021193091A (en) | Intranasal epinephrine preparations and methods for treatment of disease | |
| KR100686901B1 (en) | Medicinal compositions for application to mucosa | |
| JPH11507019A (en) | Stable liquid dispersion of water in homogeneous perfluorochemical for administration of drugs to the lungs of animals | |
| EP1420760A2 (en) | Aerosolized decongestants for the treatment of sinusitis | |
| KR20010022636A (en) | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols | |
| EA003405B1 (en) | Method and device for delivering an aerosolized active agent to the lungs of a human patient | |
| BRPI0610352A2 (en) | oral drug delivery system and methods of using it | |
| KR20090060348A (en) | Pulmonary surfactant formulations and methods for promoting mucus clearance | |
| KR20190055057A (en) | Composition, apparatus and method for the treatment of alcohol use disorders | |
| US20200268656A1 (en) | Nebulized Ethanol for Internal Disinfecting and Improvement | |
| RU2341267C2 (en) | Liquid preparation containing tobramycine | |
| IT202000005026A1 (en) | Lactoferrin for inhalation use with antiviral action | |
| Tandel et al. | Protein and peptide delivery through respiratory pathway | |
| US20230320978A1 (en) | Compositions and methods for lowering intracranial pressure | |
| CN1235596C (en) | Spray for treating asthma and its preparing method | |
| CN114903889B (en) | Lizatriptan nasal spray and preparation method thereof | |
| JP2006511617A (en) | Pharmaceutical porous particles | |
| US6645467B2 (en) | Composition and method for decreasing upper respiratory airway resistance | |
| CN110917138B (en) | Two-cavity nasal spray containing oxymetazoline hydrochloride for treating rhinitis | |
| US20210403550A1 (en) | Formulation of tocilizumab and method for treating covid-19 by inhalation | |
| JP7475065B2 (en) | Medication, alveolar lavage fluid, and nebulizer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210615 |
|
| RJ01 | Rejection of invention patent application after publication |